View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 10, 2017updated 13 Jul 2022 10:11am

Boehringer begins enrolment in Phase II trial of BI 655064 to treat lupus nephritis

Pharmaceutical company Boehringer Ingelheim has begun patient enrolment in the Phase II clinical trial of BI 655064 for the treatment of lupus nephritis (LN).

Pharmaceutical company Boehringer Ingelheim has begun patient enrolment in the Phase II clinical trial of BI 655064 for the treatment of lupus nephritis (LN).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Part of a collaboration between AbbVie and Boehringer Ingelheim, BI 655064 is a humanised mouse, anti-human monoclonal antibody being developed as an antagonist to CD40 present on B-cells in whole blood.

The double-blind, randomised, placebo-controlled, multi-centre Phase II trial will enrol a total of 120 patients in North America, Western and Eastern Europe, Asia and Australia.

Trial’s coordinating principal investigator Dr David Jayne said: “This trial is of great importance for patients with lupus nephritis, since it investigates a new and promising mechanism that has the potential to both improve kidney function and control of their lupus symptoms.”

"Our innovative trial is designed to include patients with active LN class III and IV and we are glad to be able to investigate a new potential treatment option for patients in urgent need."

The trial is designed to assess the efficacy and safety of three different sub-cutaneous doses of the drug over a period of 52 weeks in patients with active LN class III and IV.

Boehringer Ingelheim immunology / CNS therapeutic area head Dr Jan Poth said: “Boehringer Ingelheim is dedicated to transforming lives of patients with immunological diseases.

“Our innovative trial is designed to include patients with active LN class III and IV and we are glad to be able to investigate a new potential treatment option for patients in urgent need.”

The trial’s primary endpoint is complete renal response at week 52, while other evaluations include overall systemic lupus erythematosus (SLE) symptoms, patient reported outcomes and fatigue.

Subjects participating in the trial will receive treatment with BI 655064 and standard-of-care therapy combination for one year, following which responders to therapy will be provided treatment for an additional two years.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena